IGF-1 as a Growth Hormone Mediator
Insulin-like growth factor 1 (IGF-1) is a 70-amino acid single-chain polypeptide structurally related to proinsulin. It is produced primarily in the liver in response to growth hormone (GH) stimulation and mediates most of GH’s anabolic and growth-promoting effects on peripheral tissues. The GH/IGF-1 axis is one of the most fundamental regulators of somatic growth, tissue maintenance, and metabolic homeostasis in mammals.
IGF-1 acts through the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor that activates the phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK/ERK signaling cascades upon ligand binding. These pathways govern cell survival, proliferation, differentiation, and protein synthesis across virtually all tissues in the body. In circulation, approximately 99% of IGF-1 is bound to IGF-binding proteins (IGFBPs), primarily IGFBP-3, which regulate its bioavailability and extend its circulating half-life to 12–15 hours.
IGF-1 LR3: Extended Half-Life Variant
IGF-1 Long R3 (IGF-1 LR3) is a recombinant analog of human IGF-1 in which the glutamic acid at position 3 is replaced by arginine (R3) and a 13-amino acid N-terminal extension is added. These modifications were designed to reduce binding to IGFBPs, dramatically increasing the free, biologically active fraction of the peptide. The reduced IGFBP binding extends IGF-1 LR3’s effective biological half-life to approximately 20–30 hours compared to the approximately 15–20 minutes half-life of free (unbound) native IGF-1.
IGF-1 LR3 was developed primarily as a research tool to study IGF-1 biology without the confounding variable of IGFBP binding, which makes it difficult to control the dose-response relationship in cell culture and animal experiments. Its prolonged activity also makes it useful for studying sustained IGF-1 signaling in vivo. It is important to note that IGF-1 LR3 is not an approved pharmaceutical compound and is used exclusively in research contexts.
Muscle Protein Synthesis Research
The stimulatory effect of IGF-1 on skeletal muscle protein synthesis is among its most extensively studied biological actions. IGF-1 activates PI3K/Akt/mTOR signaling in muscle cells, which drives translation initiation through phosphorylation of p70S6 kinase and 4E-BP1 — key regulators of protein synthesis rate. This pathway is also activated by amino acids and exercise, and IGF-1 signaling acts synergistically with these stimuli.
In vitro studies using differentiated skeletal muscle cell lines and primary myotubes have shown that IGF-1 and IGF-1 LR3 treatment increases rates of protein synthesis, as measured by isotope incorporation, and hypertrophic responses including myotube diameter. Animal studies using IGF-1 transgenic mice or direct muscular injection of IGF-1-expressing viral vectors have demonstrated substantial muscle hypertrophy and enhanced force generation.
Research in human subjects — primarily involving replacement therapy for GH deficiency — has confirmed the anabolic effects of IGF-1 in muscle, showing increases in lean body mass, muscle cross-sectional area on imaging, and skeletal muscle protein fractional synthetic rate in metabolic tracer studies.
Satellite Cell Activation Studies
Satellite cells are the resident stem cells of skeletal muscle, residing beneath the basal lamina of muscle fibers in a quiescent state under normal conditions. Following muscle damage or during hypertrophic stimulation, satellite cells are activated to proliferate and differentiate, fusing with existing muscle fibers to support repair and growth. IGF-1 is one of the primary signals governing satellite cell activation and differentiation.
Research has demonstrated that IGF-1 promotes satellite cell proliferation through MAPK/ERK pathway activation and drives differentiation toward myogenic commitment via PI3K/Akt signaling. Studies in mouse models comparing satellite cell behavior in wild-type versus IGF-1-overexpressing animals show markedly enhanced regenerative capacity in the IGF-1 transgenic background following experimentally induced muscle damage.
Local production of IGF-1 by muscle fibers themselves — distinct from hepatic endocrine IGF-1 — has been characterized as mechanical growth factor (MGF), a splice variant of the IGF-1 gene generated in response to muscle stretch and damage. MGF appears particularly important for the early satellite cell activation response following exercise.
Metabolic Effects
Beyond muscle, IGF-1 exerts important metabolic effects including insulin-like actions on glucose metabolism. Like insulin, IGF-1 promotes glucose uptake in muscle and adipose tissue through activation of the GLUT4 glucose transporter. Consequently, elevated IGF-1 levels, whether endogenous or from administration, produce hypoglycemia — a recognized adverse effect in IGF-1 replacement therapy that requires careful monitoring.
Research has also demonstrated that IGF-1 promotes adipogenesis (differentiation of preadipocytes into adipocytes) and influences lipid metabolism, with complex effects that depend on the relative activation of different downstream signaling branches. The metabolic effects of IGF-1 interact with insulin signaling through shared receptor and post-receptor components.
Cancer Research Considerations: The Dual Nature
IGF-1 signaling occupies a critical and complex position in cancer biology. The same pro-proliferative and anti-apoptotic signaling that makes IGF-1 anabolic in normal tissues also supports tumor cell survival and growth. Epidemiological studies have associated higher circulating IGF-1 levels with increased risk of several cancers, including breast, prostate, colorectal, and lung cancers. Mechanistically, IGF-1R signaling in tumor cells mediates resistance to apoptosis, promotes metastatic migration, and activates oncogenic transcription factors.
These cancer-related considerations represent a critical research caution surrounding IGF-1 and IGF-1 LR3. The strong mitogenic and anti-apoptotic properties that drive interest in anabolic applications are theoretically capable of accelerating growth of pre-existing malignant or pre-malignant cells. IGF-1R inhibitors have been extensively researched as anti-cancer agents — the biological converse of pro-proliferative IGF-1 research. This dual nature demands careful consideration in the design and interpretation of IGF-1 research protocols.
References
- Laron Z. “Insulin-like growth factor 1 (IGF-1): a growth hormone.” Molecular Pathology. 2001;54(5):311–316.
- Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. “Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice.” Journal of Cell Biology. 2002;157(1):137–148.
- Adams GR. “Invited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation.” Journal of Applied Physiology. 2002;93(3):1159–1167.
- Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.” Lancet. 2004;363(9418):1346–1353.
- Firth SM, Baxter RC. “Cellular actions of the insulin-like growth factor binding proteins.” Endocrine Reviews. 2002;23(6):824–854.